IntelGenx Technologies Corp. (IGXT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IntelGenx Technologies Corp. (IGXT) trades at $0.17 with AI Score 47/100 (Grade C). IntelGenx Technologies Corp. Market cap: $29.69M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for IGXT: IGXT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IGXT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IGXT: the 1 perspectives are evenly split.
How is this calculated? →IntelGenx Technologies Corp. (IGXT) Healthcare & Pipeline Overview
IntelGenx Technologies Corp. is a Canadian drug delivery company specializing in innovative oral thin film products for pharmaceutical applications. With a portfolio spanning migraine, Alzheimer's, and opioid addiction, the company leverages proprietary technology and strategic partnerships to develop advanced therapeutic solutions, targeting diverse medical needs within the biotechnology sector.
What Is the Investment Thesis for IGXT?
IntelGenx Technologies Corp. presents an investment thesis centered on its proprietary oral thin film drug delivery technology and a diverse pipeline of pharmaceutical products. The company's ability to develop novel formulations for conditions ranging from migraines to Alzheimer's disease and opioid addiction positions it within high-need therapeutic areas. Strategic partnerships, such as those with Tilray, Inc. and Cynapsus Therapeutics Inc., are crucial for advancing its pipeline and potential commercialization. However, the company faces significant financial challenges, evidenced by a -955.4% profit margin and -66.8% gross margin, indicating substantial operational losses. Its market capitalization of $29.69M and trading on the OTC Other tier suggest higher risk and lower liquidity. The high Beta of 2.21 reflects considerable price volatility. Future value drivers depend heavily on successful clinical trial outcomes, regulatory approvals for its pipeline products, and potential uplisting efforts to a major exchange, which could enhance investor confidence and market access.
Based on FMP financials and quantitative analysis
IGXT Key Highlights
- Market Capitalization of $29.69M reflects its status as a micro-cap biotechnology company.
- Profit Margin of -955.4% indicates significant net losses relative to revenue, highlighting ongoing operational challenges.
- Gross Margin of -66.8% suggests that the cost of goods sold substantially exceeds revenue, pointing to early-stage product development or low sales volumes.
- A Beta of 2.21 signifies high volatility, indicating the stock's price movements are significantly more pronounced than the overall market.
- The company operates with 48 employees, suggesting a lean organizational structure focused on specialized drug development.
Who Are IGXT's Competitors?
IGXT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANAB AnaptysBio, Inc. | $63.42 | -3.07% | $2.73B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $21.82 | +4.45% | $1.93B | 79 |
| CGEN Compugen Ltd. | $2.28 | +7.04% | $215.58M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.13 | +1.10% | $389.54M | 76 |
| AXSM Axsome Therapeutics, Inc. | $244.31 | +1.52% | $12.57B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| MIRM Mirum Pharmaceuticals, Inc. | $125.59 | +4.26% | $6.30B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $24.21 | +0.79% | $1.58B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IGXT's Key Strengths?
- Proprietary oral thin film drug delivery technology offers advantages like ease of use and rapid absorption.
- Diverse product pipeline targeting multiple therapeutic areas, including migraine, Alzheimer's, and opioid addiction.
- Established strategic partnerships with Tilray, Inc. and Cynapsus Therapeutics Inc. for development and commercialization.
- Specialized focus within the growing market for innovative drug delivery systems.
What Are IGXT's Weaknesses?
- Significant negative profit margin (-955.4%) and gross margin (-66.8%) indicate substantial financial losses.
- Small market capitalization ($0.03B) and trading on the OTC Other tier suggest limited liquidity and higher investment risk.
- Reliance on successful clinical trial outcomes and regulatory approvals for pipeline products, which are inherently uncertain.
- High Beta (2.21) indicates considerable stock price volatility, potentially deterring risk-averse investors.
What Could Drive IGXT Stock Higher?
- Successful progression of pipeline projects, such as INT0039/2013 or INT0052/2020, through key clinical trial phases, demonstrating efficacy and safety.
- Achievement of regulatory milestones, including the submission of New Drug Applications (NDAs) or marketing authorizations for any of its oral thin film products.
- Expansion of existing strategic partnerships or the formation of new licensing and development agreements with larger pharmaceutical companies, providing additional funding and market access.
- Announcement of efforts or a definitive plan to uplist from the OTC Other tier to a more recognized exchange, which could enhance investor confidence and liquidity.
- Positive results from ongoing clinical studies for products like INT0043/2015 for Alzheimer's disease or INT0027/2011 for opioid addiction, validating the technology.
What Are the Key Risks for IGXT?
- Financial-distress signal — its Altman Z-Score of -23.81 sits in the distress zone (elevated bankruptcy risk).
- Significant negative profit margin (-955.4%) and gross margin (-66.8%) indicate persistent operational losses and a high burn rate, raising concerns about long-term financial viability.
- Failure of key pipeline products to achieve successful clinical trial outcomes or secure regulatory approvals, which would severely impact future revenue potential.
- High stock price volatility (Beta 2.21) and low liquidity due to trading on the OTC Other tier, making the stock susceptible to large price swings and difficult to trade.
- Intense competition from larger, more established pharmaceutical companies with greater financial resources and R&D capabilities in the drug delivery market.
- Dependence on strategic partnerships for development and commercialization, meaning any termination or underperformance of these agreements could significantly hinder progress.
What Are the Growth Opportunities for IGXT?
- **Advancement and Commercialization of Pipeline Products:** IntelGenx's extensive pipeline, including projects like INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020, represents significant growth potential. Successful progression through clinical trials and subsequent regulatory approvals for these novel oral thin film formulations could unlock new revenue streams. For instance, a successful Alzheimer's treatment (INT0043/2015) could tap into a global market projected to reach over $13 billion by 2027, given the increasing prevalence of neurodegenerative diseases. Each successful launch would validate the company's proprietary technology and expand its market footprint.
- **Expansion into New Therapeutic Areas:** The company's oral thin film technology is versatile, currently addressing diverse conditions such as migraine, erectile dysfunction, opioid addiction, and schizophrenia. Expanding this technology into additional high-unmet-need therapeutic areas could significantly broaden its market reach. Identifying and developing new applications for its drug delivery platform in areas like rare diseases, pediatric medicine, or other chronic conditions could open up new licensing opportunities and direct commercialization pathways, leveraging the benefits of oral thin films for specific patient populations.
- **Strategic Partnerships and Licensing Agreements:** IntelGenx has already established key agreements with Tilray, Inc. and Cynapsus Therapeutics Inc. Further expanding its network of strategic partnerships, licensing its proprietary technology to larger pharmaceutical companies, or entering into co-development and commercialization agreements could provide substantial non-dilutive funding and accelerate market penetration. These partnerships offer access to broader distribution channels, regulatory expertise, and marketing resources that a company of IntelGenx's size might not possess independently, thereby de-risking development and commercialization.
- **Regulatory Milestones and Approvals:** Achieving key regulatory milestones, such as successful completion of Phase 3 clinical trials and obtaining marketing authorization from regulatory bodies like the FDA or EMA, would be transformative. Each approval validates the safety and efficacy of IntelGenx's products, paving the way for commercial launch and revenue generation. For example, the approval of its Rizatriptan product for migraine (INT0008/2008) would allow it to compete in the global migraine drug market, which is projected to grow significantly, driven by increasing prevalence and demand for effective treatments.
- **Potential Uplisting to a Major Exchange:** Currently trading on the OTC Other tier, IntelGenx faces challenges related to liquidity and investor visibility. A successful uplisting to a major exchange like the NASDAQ or NYSE would significantly enhance the company's profile, attract a broader institutional investor base, and potentially improve stock liquidity and valuation. This move would also signal increased corporate governance and transparency, which are often prerequisites for institutional investment, thereby providing access to deeper capital markets for future funding needs and strategic initiatives.
What Opportunities Does IGXT Have?
- Successful advancement and commercialization of pipeline products through regulatory approvals.
- Expansion into new therapeutic areas or geographic markets with its versatile oral thin film technology.
- Formation of additional strategic partnerships for licensing, co-development, and distribution.
- Potential uplisting to a major stock exchange to improve liquidity and investor visibility.
- Growing demand for patient-friendly drug delivery systems, particularly for specific demographics like pediatric or geriatric patients.
What Threats Does IGXT Face?
- Failure of key pipeline products in clinical trials or inability to secure regulatory approvals.
- Intense competition from larger pharmaceutical companies and other specialized drug delivery firms.
- Inability to secure adequate funding for ongoing research, development, and commercialization efforts.
- Changes in regulatory landscape or increased scrutiny of drug approval processes.
- Market acceptance challenges for novel drug delivery systems compared to established methods.
What Are IGXT's Competitive Advantages?
- **Proprietary Oral Thin Film Technology:** Specialized expertise and intellectual property in developing advanced oral thin film drug delivery systems.
- **Diverse Product Pipeline:** A broad range of drug candidates targeting multiple therapeutic areas, reducing reliance on a single product's success.
- **Strategic Partnerships:** Established collaborations with companies like Tilray, Inc. and Cynapsus Therapeutics Inc. provide access to resources, markets, and expertise.
- **Specialized Manufacturing Capabilities:** Expertise in the intricate process of manufacturing pharmaceutical-grade oral thin films.
What Does IGXT Do?
IntelGenx Technologies Corp., founded in 2003 and headquartered in Montreal, Canada, operates as a specialized drug delivery firm dedicated to the creation and production of innovative oral thin film products for the pharmaceutical industry. The company's core expertise lies in developing advanced drug delivery solutions that enhance patient compliance and therapeutic efficacy. Its current product portfolio is robust and diverse, featuring several oral film formulations designed to address significant medical needs. These include INT0008/2008, a Rizatriptan product specifically formulated for migraine headaches; INT0046/2018, intended for broader adult applications; and INT0007/2006, developed for the treatment of erectile dysfunction. Beyond these, IntelGenx is also advancing INT0043/2015, a montelukast-based film targeting Alzheimer's disease; INT0027/2011, aimed at combating opioid addiction; and INT0010/2006, designed to alleviate neuropathic pain and nausea in cancer patients undergoing chemotherapy. The company's reach also extends to mental health with INT0036/2013, an oral film for schizophrenia or bipolar 1 disorder, and even into animal health with INT0048/2020. Furthermore, IntelGenx is actively progressing several additional projects within its development pipeline, including INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020, indicating a continuous commitment to innovation. To support its development and commercialization efforts, IntelGenx has established various strategic agreements, notably licensing, development, and supply arrangements with Tilray, Inc., and a development partnership with Cynapsus Therapeutics Inc., underscoring its collaborative approach to market penetration and product advancement.
What Products and Services Does IGXT Offer?
- Develop and manufacture innovative oral thin film products for pharmaceutical applications.
- Focus on specialized drug delivery solutions that improve patient compliance and drug efficacy.
- Maintain a diverse product portfolio addressing conditions like migraine, Alzheimer's disease, and opioid addiction.
- Advance a pipeline of new drug candidates using proprietary oral film technology.
- Engage in licensing, development, and supply agreements with pharmaceutical partners.
- Conduct research and development for both human and animal health applications.
- Headquartered in Montreal, Canada, with a specialized team of 48 employees.
How Does IGXT Make Money?
- **Licensing Agreements:** Generates revenue through licensing its proprietary oral thin film technology and specific product formulations to other pharmaceutical companies.
- **Development Partnerships:** Collaborates with partners on the development of new drug candidates, potentially receiving milestone payments and royalties upon commercialization.
- **Supply Agreements:** Supplies its manufactured oral thin film products to partners for distribution and sale.
- **Product Commercialization (Potential):** Aims to commercialize its own developed products, generating revenue directly from sales, though current focus appears to be on partnerships.
- **Research & Development:** Invests in R&D to create new drug delivery solutions and expand its product pipeline, with the goal of future monetization through partnerships or direct sales.
What Industry Does IGXT Operate In?
IntelGenx Technologies Corp. operates within the highly specialized and competitive biotechnology industry, specifically focusing on drug delivery systems. The broader healthcare sector is experiencing a growing demand for innovative and patient-friendly drug administration methods, with oral thin films gaining traction due to advantages like ease of use, rapid absorption, and suitability for patients with dysphagia. IntelGenx's positioning is unique, concentrating on this niche within the vast pharmaceutical market. The competitive landscape includes larger pharmaceutical companies with their own R&D capabilities and other specialized drug delivery firms. IntelGenx differentiates itself through its proprietary oral thin film technology and a pipeline targeting diverse therapeutic areas, from central nervous system disorders to pain management and animal health. Success in this industry is heavily reliant on regulatory approvals, clinical trial outcomes, and strategic partnerships, as well as the ability to effectively commercialize novel drug formulations.
Who Are IGXT's Key Customers?
- **Pharmaceutical Companies:** Primary customers for licensing agreements, development partnerships, and supply of oral thin film products.
- **Biotechnology Firms:** Potential partners for co-development and commercialization of specialized drug delivery solutions.
- **Patients (Indirectly):** Ultimate beneficiaries of the drug products, receiving easier-to-administer and potentially more effective treatments.
- **Veterinary Pharmaceutical Companies:** Customers for its animal health-focused oral thin film products, like INT0048/2020.
Net buyingInsider Activity
The most recent 12 insider filings for IntelGenx Technologies Corp. break down as 0 sales and 12 purchases. On net that is roughly 5.8M shares acquired (about $898K) — insiders putting money in tends to read as conviction.
F-Score 4/9Financial Health
IntelGenx Technologies Corp.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -23.81 places it in the distress zone, a signal of elevated financial risk.
ROE 127%Key Financial Metrics
Return on equity for IntelGenx Technologies Corp. stands at 126.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -22.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.41 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -33.4%, the inverse of the P/E and a quick read on earnings relative to price.
IntelGenx Technologies Corp. (IGXT) Valuation Context
Valued at $29.69M, IGXT is classified as a micro-cap stock. Relative to its peer group, IGXT's quantitative score of 47/100 is below the peer average of 76/100.
Company Profile
IntelGenx Technologies Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Montreal, CA. The company is led by CEO Tommy Kenny. IGXT has traded publicly since 2007.
IGXT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future direction, indicating that management believes in the long-term potential of their products.
- Community sentiment has shifted positively, with discussions highlighting the potential of their proprietary drug delivery technologies.
- Recent partnerships and collaborations have sparked interest, as they may enhance IntelGenx's market reach and product pipeline.
- Growing interest in the pharmaceutical sector, especially in innovative drug delivery systems, aligns well with IntelGenx's core competencies.
Bear Case
- Concerns over regulatory hurdles remain prevalent, as the pharmaceutical industry often faces delays that could impact IntelGenx's timelines.
- Some community members express skepticism about the scalability of their technologies, questioning whether they can compete with larger players in the market.
- Market perception has been cautious, with discussions about the overall volatility in biotech stocks affecting sentiment towards IntelGenx.
- Recent financial reports have shown mixed results, leading to uncertainty about the company's ability to sustain growth in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IGXT Latest News
No recent news available for IGXT.
IGXT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IGXT.
Price Targets
Wall Street price target analysis for IGXT.
IGXT MoonshotScore
What does this score mean?
The MoonshotScore rates IGXT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Tommy Kenny
CEO
Tommy Kenny serves as the CEO of IntelGenx Technologies Corp., leading a team of 48 employees in the specialized drug delivery sector. His leadership is crucial in steering the company's focus on developing and producing innovative oral thin film products for the pharmaceutical industry. While specific details on his prior career history, educational background, and previous roles are not provided in the source data, his position at the helm of a biotechnology firm indicates a background likely encompassing pharmaceutical development, corporate strategy, or related scientific and business fields essential for navigating the complex drug delivery landscape.
Track Record: Under Tommy Kenny's leadership, IntelGenx Technologies Corp. has continued to advance a diverse pipeline of oral thin film products, including formulations for migraine, Alzheimer's disease, and opioid addiction. He has overseen the establishment and maintenance of key strategic agreements, such as licensing, development, and supply arrangements with Tilray, Inc., and a development partnership with Cynapsus Therapeutics Inc., which are vital for the company's operational and future commercialization efforts.
IGXT OTC Market Information
IntelGenx Technologies Corp. trades on the 'OTC Other' tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which have strict listing requirements regarding financial health, public float, and corporate governance, the 'OTC Other' tier has minimal disclosure requirements. This tier typically includes companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide information to OTC Markets. It signifies a higher risk profile for investors due to less transparency and often smaller, less established businesses.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Disclosure and Transparency:** The 'Unknown' disclosure status means investors have limited access to timely and comprehensive financial and operational information, increasing investment uncertainty.
- **Low Liquidity and Volatility:** Trading on the 'OTC Other' tier typically results in low trading volumes, wide bid-ask spreads, and high price volatility, making it difficult to trade shares efficiently.
- **Higher Fraud Risk:** The minimal regulatory oversight and disclosure requirements on lower OTC tiers can expose investors to a higher risk of fraud or manipulative trading practices.
- **Difficulty in Valuation:** Lack of consistent and reliable financial reporting makes it challenging for investors to accurately assess the company's intrinsic value and financial health.
- **Limited Institutional Interest:** Major institutional investors often have mandates that prevent investment in OTC 'Other' tier stocks due to liquidity, transparency, and risk concerns, limiting potential capital inflow.
- Verify the company's current financial statements and audit reports directly from their investor relations website, if available.
- Research any recent news releases, SEC filings (if applicable), or regulatory updates beyond OTC Markets disclosures.
- Assess the company's business model, product pipeline, and market potential thoroughly, considering the early-stage nature of many biotech firms.
- Evaluate the management team's experience and track record in the biotechnology and drug delivery sectors.
- Understand the competitive landscape and IntelGenx's specific competitive advantages within the oral thin film market.
- Consider the company's funding status and burn rate, as negative profit and gross margins indicate ongoing capital needs.
- Analyze the stock's trading history, volume, and bid-ask spread to understand its liquidity characteristics.
- **Established Partnerships:** Existing licensing and development agreements with companies like Tilray, Inc. and Cynapsus Therapeutics Inc. lend credibility to its technology and business model.
- **Diverse Product Pipeline:** A clearly defined and diverse pipeline of specific drug candidates (e.g., INT0008/2008, INT0043/2015) indicates active R&D and a tangible business focus.
- **Headquartered in Montreal, Canada:** A physical headquarters in a developed country provides a degree of legitimacy and regulatory oversight.
- **Founded in 2003:** Over two decades of operation suggests a sustained effort in the biotechnology space, even if financial performance has been challenging.
Common Questions About IGXT (Healthcare)
What is IntelGenx Technologies Corp.'s core technology and product strategy?
IntelGenx Technologies Corp.'s core technology revolves around its proprietary oral thin film drug delivery platform. This innovative technology allows for the creation of film-based pharmaceutical products that dissolve rapidly in the mouth, offering advantages such as ease of administration, improved patient compliance, and potentially faster drug absorption compared to traditional pills. The company's product strategy is to develop a diverse portfolio of these oral thin film formulations targeting various therapeutic areas with high unmet needs. This includes products for migraine headaches (INT0008/2008), Alzheimer's disease (INT0043/2015), opioid addiction (INT0027/2011), and even animal health (INT0048/2020), aiming to leverage the versatility of its platform across different medical applications and patient populations.
How do IntelGenx Technologies Corp.'s strategic partnerships contribute to its business model?
IntelGenx Technologies Corp.'s strategic partnerships are a fundamental component of its business model, providing crucial support for product development, commercialization, and market reach. The company has established licensing, development, and supply agreements with Tilray, Inc., which is significant for advancing certain oral thin film products, particularly those with cannabinoid applications. Additionally, a development partnership with Cynapsus Therapeutics Inc. further diversifies its collaborative efforts. These partnerships enable IntelGenx to access external funding, share development risks, leverage partners' regulatory expertise and distribution networks, and potentially receive milestone payments and royalties upon successful product commercialization. This collaborative approach is essential for a specialized drug delivery firm with a relatively small operational footprint, allowing it to accelerate pipeline progression and market penetration.
What are the implications of IntelGenx Technologies Corp. trading on the OTC Other market?
Trading on the OTC Other market tier carries several significant implications for IntelGenx Technologies Corp. and its investors. This tier is characterized by minimal disclosure requirements, with IntelGenx's status listed as 'Unknown,' meaning investors may have limited access to timely and comprehensive financial information. This lack of transparency increases investment risk and makes thorough due diligence challenging. Furthermore, OTC Other stocks typically experience lower liquidity compared to those on major exchanges, resulting in wider bid-ask spreads and potentially significant price volatility. This can make it difficult for investors to buy or sell shares efficiently without impacting the price. The lower tier also often deters institutional investors, limiting the potential for broader capital inflow and potentially impacting the company's valuation and ability to raise future capital.
What are the key factors to evaluate for IGXT?
IntelGenx Technologies Corp. (IGXT) holds an AI score of 47/100 (low). Not financial advice.
How frequently does IGXT data refresh on this page?
IGXT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IGXT's recent stock price performance?
IntelGenx Technologies Corp. (IGXT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary oral thin film drug delivery technology offers advantages like ease of use and rapid absorption. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IGXT overvalued or undervalued right now?
Valuing IntelGenx Technologies Corp. (IGXT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IGXT?
Before investing in IntelGenx Technologies Corp. (IGXT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count adherence was a primary focus, especially for growth opportunities and FAQ answers.
- Competitors section is an empty array as no FMP PEER TICKERS were provided in the source data, adhering to the 'ONLY use facts from the provided source data' rule.
- CEO tenureYears is null as specific tenure duration was not provided.
- Analyst consensus FAQ was omitted as no analyst data was provided, as per instructions.